Crossmark

Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment

Crossref DOI link: https://doi.org/10.1007/s12032-025-02821-2

Published Online: 2025-06-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tanveer, Laiba

Batool, Salma

Mubeen, Hira

Shahid, Izzah
Funding

Funding for this research was provided by:

Universidad Pública de Navarra
License Information

Text and Data Mining valid from 2025-06-25

Version of Record valid from 2025-06-25
More Information

Article History

Received: 10 March 2025

Accepted: 23 May 2025

First Online: 25 June 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below